The Accredited Duchenne Centers (ADC) Program, spearheaded by the World Duchenne Organization (WDO), is a pioneering global initiative designed to standardize and elevate care for individuals living with Duchenne Muscular Dystrophy (DMD) across all ages. DMD, the most common genetic neuromuscular disorder in children, leads to progressive muscle degeneration, affecting primarily boys and men due to its X-linked inheritance. As reported by BMC part of Springer Nature, while promising treatments are developing, current management relies heavily on optimal preventative and symptomatic care to extend life expectancy and improve quality of life.
Recognizing the significant variation in DMD care worldwide, the ADC Program aims to ensure that all care centers provide up-to-date, high-quality, and uniform care in accordance with the latest international care considerations and consensus guidelines. Existing standards and guidelines cover key domains such as diagnosis, neuromuscular rehabilitation, respiratory and cardiac health, bone and orthopedic care, emergency and psychosocial management, and the transition from childhood to adulthood. However, adherence to these guidelines varies, which can result in preventable complications and disparities in patient outcomes.
The ADC Program bridges this gap through a rigorous, five-step accreditation process developed in collaboration with an international Advisory Board of experts and patient representatives. The process starts with center registration, followed by a screening questionnaire to assess compliance with care standards. Eligible centers then undergo an in-depth visitation, where multidisciplinary professionals and patient representatives conduct structured interviews with staff, patients, and families. Patient experiences and perspectives are incorporated through dedicated questionnaires, ensuring that care is evaluated holistically.
Accredited centers must demonstrate comprehensive, coordinated care that aligns with current guidelines. If minor gaps are identified, centers receive tailored feedback and support to make improvements before accreditation is granted. Accredited status is maintained for five years, during which centers must participate in ongoing education to keep up with advances in DMD care. Reaccreditation or earlier review is required if significant changes occur within the center.
Transparency and continuous improvement are embedded in the program through the use of a FAIR (Findable, Accessible, Interoperable, Reusable) database. This system stores interview recordings and questionnaire results, enabling the identification of barriers to high-quality care and informing future education and support efforts. The data help highlight which criteria are most challenging for centers and guide the evolution of the program.
By fostering a global network of accredited centers, the ADC Program ensures that people with DMD and their families have access to reliable, high-standard care no matter where they live. The inclusion of patient and family voices, commitment to continuous education, and transparent data practices set a new benchmark for rare disease care programs worldwide. As the ADC Program continues its rollout, it holds the promise of reducing disparities and improving the lives of all those affected by Duchenne Muscular Dystrophy.
